218 related articles for article (PubMed ID: 32871847)
21. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.
Ye Z; Wang Y; Colunga-Lozano LE; Prasad M; Tangamornsuksan W; Rochwerg B; Yao L; Motaghi S; Couban RJ; Ghadimi M; Bala MM; Gomaa H; Fang F; Xiao Y; Guyatt GH
CMAJ; 2020 Jul; 192(27):E756-E767. PubMed ID: 32409522
[TBL] [Abstract][Full Text] [Related]
22. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
23. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
Ledford H
Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
[No Abstract] [Full Text] [Related]
24. Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
[TBL] [Abstract][Full Text] [Related]
25. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.
Zhou W; Liu Y; Tian D; Wang C; Wang S; Cheng J; Hu M; Fang M; Gao Y
Signal Transduct Target Ther; 2020 Feb; 5(1):18. PubMed ID: 32296012
[No Abstract] [Full Text] [Related]
26. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
27. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
28. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
Perricone C; Conigliaro P; Ciccacci C; Marcucci E; Cafaro G; Bartoloni E; Perricone R; Novelli G; Borgiani P; Gerli R
Clin Exp Rheumatol; 2020; 38(3):580. PubMed ID: 32452345
[No Abstract] [Full Text] [Related]
29. A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
Di Virgilio F; Tang Y; Sarti AC; Rossato M
Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolytic therapy in patients with COVID-19 and acute respiratory distress syndrome: Is this a feasible approach?
Savioli F; Rocha L; Góis A; Nakano LC
J Trauma Acute Care Surg; 2020 Dec; 89(6):e187-e188. PubMed ID: 32868539
[No Abstract] [Full Text] [Related]
31. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
32. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
33. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
Soto M; diZerega G; Rodgers KE
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
[TBL] [Abstract][Full Text] [Related]
34. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Matucci-Cerinic M; Bruni C; Allanore Y; Clementi M; Dagna L; Damjanov NS; de Paulis A; Denton CP; Distler O; Fox D; Furst DE; Khanna D; Krieg T; Kuwana M; Lee EB; Li M; Pillai S; Wang Y; Zeng X; Taliani G
Ann Rheum Dis; 2020 Jun; 79(6):724-726. PubMed ID: 32349982
[TBL] [Abstract][Full Text] [Related]
35. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
36. Lack of tocilizumab effect on mortality in COVID19 patients.
Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
[TBL] [Abstract][Full Text] [Related]
37. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
[TBL] [Abstract][Full Text] [Related]
38. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
39. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
40. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Jeon S; Ko M; Lee J; Choi I; Byun SY; Park S; Shum D; Kim S
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
